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Abstract: In vitro cancer drug testing carries a low predictive value. We developed the human
leiomyoma–derived matrix “Myogel” to better mimic the human tumor microenvironment (TME). We
hypothesized that Myogel could provide an appropriate microenvironment for cancer cells, thereby
allowing more in vivo–relevant drug testing. We screened 19 anticancer compounds, targeting the
epidermal growth factor receptor (EGFR), MEK, and PI3K/mTOR on 12 head and neck squamous cell
carcinoma (HNSCC) cell lines cultured on plastic, mouse sarcoma–derived Matrigel (MSDM), and
Myogel. We applied a high-throughput drug screening assay under five different culturing conditions:
cells in two-dimensional (2D) plastic wells and on top or embedded in Matrigel or Myogel. We then
compared the efficacy of the anticancer compounds to the response rates of 19 HNSCC monotherapy
clinical trials. Cancer cells on top of Myogel responded less to EGFR and MEK inhibitors compared
to cells cultured on plastic or Matrigel. However, we found a similar response to the PI3K/mTOR
inhibitors under all culturing conditions. Cells grown on Myogel more closely resembled the response
rates reported in EGFR-inhibitor monotherapy clinical trials. Our findings suggest that a human
tumor matrix improves the predictability of in vitro anticancer drug testing compared to current 2D
and MSDM methods.
Keywords: head and neck cancer; drug screening; human tumor microenvironment; clinical trials;
in vitro 3D
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1. Introduction
Current preclinical anticancer drug testing carries a low predictive value, since only 5% of
compounds showing efficacy in in vitro tests are licensed following clinical trials [1]. Therefore,
improved predictive in vitro methods are urgently needed. We developed a human tumor
leiomyoma–derived matrix “Myogel” to better mimic the human tumor microenvironment (TME) [2,3].
Myogel provides a three-dimensional (3D) culture environment for in vitro cancer studies, preserving
the soluble factors present in the human TME by including, for example, soluble cytokines and growth
factors [3]. Myogel proteome differs greatly from mouse sarcoma–derived Matrigel [3]. We previously
demonstrated that 66% of the Myogel protein content differs from Matrigel [3]. Yet, these matrices
share several proteins such as laminin, type IV collagen, heparan sulfate proteoglycans, nidogen, and
epidermal growth factor [3]. Carcinoma cells show a markedly higher migration and invasion ability
on Myogel compared to Matrigel [2–4].
Head and neck squamous cell carcinoma (HNSCC) represents the sixth most common cancer
worldwide, with a relatively low survival rate of around 50% [5]. Treatment approaches include
surgery combined with radio-, chemo-, or epidermal growth factor receptor- (EGFR-) targeted therapy
relying on cetuximab (Erbitux). EGFR is frequently overexpressed in HNSCC [6] and its inhibitors have
shown clear anticancer effects in both in vitro and in vivo preclinical studies [7–11]. However, most
EGFR inhibitors have yielded disappointing results in HNSCC clinical trials and there are no clinically
approved predictive biomarkers for EGFR inhibitor response [12]. We propose that the presence of the
human tumor matrix, as a physiologically relevant extracellular matrix for human cancer cells, could
improve the predictability of anticancer drug testing in preclinical studies of HNSCC.
In this study, using a high-throughput drug screening method, we tested 12 HNSCC cell lines
cultured on plastic, mouse sarcoma–derived Matrigel, or Myogel using 19 anticancer compounds
targeting EGFR, MEK, and PI3K/mTOR. We compared the efficacy of the anticancer drugs tested
in vitro against the patients´ response rates in 19 monotherapy clinical trials. We identified different
drug effects between Myogel and the other testing conditions, and demonstrated that Myogel in
in vitro drug screening replicates the best results from clinical trials.
2. Results
2.1. In Vitro Drug Screen
The cell viability readout revealed differential EGFR- and MEK-inhibitor effects between Myogel
and the other testing conditions (Figure 1A,B and Figure S1). However, cells responded similarly to
PI3K/mTOR inhibitors independent of the culturing condition (Figure 1C and Figure S1). Based on
previous studies, drug response profiles were divided into four activity classes using the drug-sensitivity
score (DSS) values and artificial cut-off points: inactive DSS < 5, low 5 ≥ DSS < 10, moderate 10 ≥
DSS < 15, and high DSS ≥ 15 [13]. Based on the DSS values, the EGFR and MEK inhibitors showed
a moderate or high activity in most cell lines cultured on plastic, and on top of or embedded in
Matrigel (Figure 1A,B and Figure S2). However, most cell lines cultured on top of or embedded in
Myogel showed a low EGFR- and MEK-inhibitor activity or no effect (Figure 1A,B and Figure S2).
Collectively, cells responded relatively similarly to the PI3K/mTOR and mTOR inhibitors across the
different culturing conditions (Figure 1C and Figure S2). mTOR inhibitors (Rapalogs: temsirolimus
and ridaforolimus) showed a relatively low activity level on most cells lines (Figure S2). In addition,
everolimus was inactive in most cell lines (Figure S2). The PI3K/mTOR inhibitor omipalisib showed a
moderate-to-high activity level across all cell lines and under the different conditions (Figure S2). Only
one cell line (UT-SCC-24B) responded to dactolisib (Figure S2). Sirolimus and PF-04691502 showed
varying a low-to-high activity level across cell lines (Figure S2). Furthermore, apitolisib exhibited a
low-to-moderate activity (Figure S2).
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Figure 1. Box plots of the average drug-sensitivity score (DSS) values for each cell line clustered
according to the drug group and the culturing condition. Cancer cells on top of and embedded in
Myogel were less responsive to EGFR (A) and MEK inhibitors (B) compared to the cells cultured on
two-dimensional (2D) plastic or Matrigel. However, for the PI3K and mTOR inhibitors (C), we observed
a similar efficacy for the drugs under all culturing conditions.
We performed the Friedman test followed by a pair-wise comparison of drug responses under five
culturing conditions (control, Myogel two-dimensional (2D), Myogel 3D, Matrigel 2D, and Matrigel
3D) for all cell lines in order to detect differences in drug efficacy [14]. Significantly different responses
between culturing conditions were observed for several drugs, particularly for the EGFR and MEK
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inhibitors (Table 1). Significant differences were consistently seen between Myogel 3D and Matrigel 3D
in the EGRF and MEK inhibitors (Table 1). The MEK inhibitor responses were significantly diminished
in Myogel compared to Matrigel (100% of all cases). The PI3K/mTOR inhibitors, omipalisib, apitolisib
and PF-04691502, were significantly less effective in Myogel 2D and 3D compared with Matrigel 3D
(Table 1). Although the mTOR inhibitor everolimus exhibited a generally weak response, it showed a
higher effect in Myogel 2D and 3D compared with Matrigel 3D (Table 1 and Figure S2). The remaining
PI3K/mTOR along with the selective mTOR inhibitors (temsirolimus, sirolimus, ridaforolimus, and
dactolisib) showed no significant differences.
2.2. Clinical Trial Data Collection
We collected data from clinical trials on the anticancer compounds used as monotherapies for
HNSCC patients until 17 March 2018 (Table 2). Only cetuximab, erlotinib, afatinib, and gefitinib were
tested in phase III trials. Erlotinib has been widely studied, but only as a combination therapy with
other treatments. No clinical trials have been performed among HNSCC patients for the following
drugs: canertinib (EGFR inhibitor); dactolisib, PF-04691502, apitolisib, and omipalisib (PI3K inhibitors);
and refametinib, binimetinib, trametinib, and pimasertib (MEK inhibitors). One phase I study of
trametinib (MEK inhibitor) was terminated at the sponsor’s discretion. All other compounds tested in
this study only reached the stage of phase I or II trials.
2.3. Comparison of In Vitro Drug Testing and Clinical Trial Responses
The response rate for each anticancer compound was calculated from our drug screen using DSS
≥ 5 as the cut-off point (Figure S2 and Table S1). We also collected the monotherapy objective response
rate (ORR) from the clinical trials (Table 2). Based on the clinical trials, the ORR for cetuximab fell
between 3.7% and 14.5% and the pooled ORR obtained using the inverse variance method for all eight
clinical trials was 10.0% (confidence interval, CI 7.0–14.0; Figure 2A, Table 2). Cells cultured on top of
(2D) or embedded (3D) in Myogel showed response rates closest to the clinical trials, at 17% (CI 4.4–37.8)
and 25% (CI 5.0–49.5) across 12 HNSCC cell lines, respectively. Other testing conditions resulted in
very high response rates to cetuximab: 67% (CI 40.0–93.3) of cells on plastic, 67% (CI 40.0–93.3) of
cells on top of, and 75% (CI 50.2–99.5) of cells embedded in Matrigel. The predictive value of Myogel
was similar to that for other EGFR inhibitors, such as afatinib and gefitinib (Figure 2B,C). Gefitinib
showed only a weak response in four clinical trials with a pooled ORR of 6% (CI 3.0–9.0; Figure 2B).
Cells cultured both on top of or embedded in Myogel showed a weak response to gefitinib at 8.3%
(CI 7.3–24.0) across 12 HNSCC cell lines. Other testing conditions resulted in higher response rates:
16.7% (CI 4.4 to 37.8%) of cells on plastic, 41.7% (CI 13.8–69.6) of cells on top of, and 50% (CI 21.7–78.3)
of cells embedded in Matrigel (Figure 2B). Based on three clinical trials of afatinib, the pooled ORR
was 10% (CI 7.0–13.0; Figure 2C). Cells on top and embedded in Myogel had a low response rate of
17% to afatinib (CI 4.4–37.8) unlike other conditions, which all exhibited a high response rate of 75%
(CI 50.2–99.5; Figure 2C).
Rapamycin analog mTOR inhibitors, such as temsirolimus which is currently in a phase II trial,
showed a high response rate, but a relatively low effect (0 ≥ DSS < 10) in each of our in vitro testing
conditions (Figure S2). Several DSS values were close to the cut-off point (DSS ≥ 5). The response rate
for temsirolimus reached 75% (CI 50.2–99.5) on plastic and embedded in Matrigel, 67% (CI 40.0–93.3) on
top of Matrigel, 83% (CI 62.2–104.4) on top of, and 50% (CI 21.7–78.3) embedded in Myogel (Figure 2D
and Table S1). A phase II clinical trial for temsirolimus resulted in promising tumor shrinkage in 39.4%
of patients, but unfortunately lacked any objective response (Figure 2D and Table 2) [15]. Another phase
II clinical trial reported only a 2.5% ORR (Figure 2D and Table 2). The pooled ORR for temsirolimus
was 2% (CI 0–10.0). One window-of-opportunity trial for sirolimus (phase I and II trials) showed
significant clinical responses with an ORR of 25% including one complete response (Table 2). The
in vitro response rate for sirolimus reached 92% (CI 76.0–107.3) on plastic and on top of Matrigel, 67%
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(CI 40.0–93.3) embedded in Matrigel, 83% (CI 62.2–104.4) on top of, and 75% (CI 50.2–99.5) embedded
in Myogel (Table S1).
Figure 2. Meta-analysis of the objective response rates (ORRs) for cetuximab, gefitinib, afatinib, and
temsirolimus monotherapy clinical trials and the response rates of in vitro drug testing. The pooled
total average for the ORRs appears as a red diamond. The in vitro response rates were calculated
using a drug-sensitivity score (DSS) value of ≥5 as the cut-off point (A–D). Data collected from
https://clinicaltrials.gov. The different doses used in the same trial are marked as a and b.
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Table 1. Comparison of the culturing conditions for each anticancer compound. Adjusted p-values were collected, and the number and percentage of significant cases
in the drug groups (EGFR, MEK, and mTOR/PI3K) were calculated. Significant differences appear in bold. (N/A, not applicable).
EGFR Myogel 2D vs.Myogel 3D
Myogel 2D
vs. control
Myogel 3D
vs. control
Myogel 3D vs.
Matrigel 2D
Myogel 3D vs.
Matrigel 3D
Myogel 2D vs.
Matrigel 3D
Myogel 2D vs.
Matrigel 2D
Control vs.
Matrigel 3D
Control vs.
Matrigel 2D
Matrigel 2D vs.
Matrigel 3D
Erbitux 1.000 0.118 0.081 0.081 0.003 0.005 0.118 1.000 1.000 1.000
Gefitinib 0.098 1.000 0.814 0.055 0.012 0.098 0.332 1.000 1.000 1.000
Erlotinib 1.000 1.000 1.000 0.454 0.142 0.142 0.454 1.000 1.000 1.000
Afatinib 1.000 0.118 0.118 0.008 0.001 0.001 0.008 1.000 1.000 1.000
Ganertinib 1.000 0.118 0.019 0.002 0.003 0.024 0.019 1.000 1.000 1.000
No. of sig. cases 0 0 1 2 4 3 2 0 0 0
% 0.0 0.0 20.0 40.0 80.0 60.0 40.0 0.0 0.0 0.0
MEK
Pimasertib 1.000 1.000 1.000 0.012 0.000 0.000 0.005 0.008 0.282 1.000
Trametinib 1.000 0.707 1.000 0.030 0.000 0.000 0.003 0.019 0.707 1.000
Refametinib 1.000 1.000 1.000 0.012 0.000 0.000 0.008 0.019 0.707 1.000
Binimetinib 1.000 1.000 1.000 0.004 0.000 0.000 0.004 0.005 0.389 1.000
TAK-733 1.000 0.707 1.000 0.012 0.000 0.000 0.003 0.019 0.528 1.000
Selumetinib 1.000 1.000 0.707 0.004 0.000 0.002 0.019 0.169 0.814 1.000
No. of sig. cases 0 0 0 6 6 6 6 5 0 0
% 0.0 0.0 0.0 100.0 100.0 100.0 100.0 83.3 0.0 0.0
mTOR/PI3K
Everolimus 1.000 1.000 1.000 0.142 0.010 0.008 0.118 0.612 1.000 1.000
Temsirolimus N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
Sirolimus N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
Ridaforolimus N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
Dactolisib N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
Apitolisib 1.000 0.707 1.000 0.528 0.067 0.008 0.098 1.000 1.000 1.000
Omipalisib 1.000 0.814 1.000 0.201 0.004 0.000 0.012 0.067 1.000 1.000
PF-04691502 1.000 1.000 1.000 0.332 0.008 0.003 0.169 0.332 1.000 1.000
No. of sig. cases 0 0 0 0 3 4 1 0 0 0
% 0.0 0.0 0.0 0.0 37.5 50.0 12.5 0.0 0.0 0.0
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Table 2. Objective response rates in clinical trials of anticancer compounds used as monotherapies in head and neck cancer patients. Data collected from
https://clinicaltrials.gov.
Clinical Trial
Number
Total
Enrollment Phase
Completion
Year
Monotherapy
Treated Patients
Responded
Patients
Evaluation
Criteria * ORR% * Notes
Afatinib
NCT01345682 483 3 2016 322 33 RECIST 1.1 10.2
NCT00514943 124 2 2013 62 5 RECIST 1.0 8.1 ORR is based on independentcentral review (ICR)
NCT01415674 61 2 2006 41 3 RECIST1.1 7.3 Neoadjuvant treatment
Gefitinib
NCT00206219a [16] 486 3 2007 158 4 RECIST 2.7 Drug dose 250 mg/day
NCT00206219b [16] 166 10 RECIST 7.6 Drug dose 500 mg/day
NCT00015964 [17] 51 2 2005 47 5 N/A 10.6
NCT01185158 [18] 70 2 2004 70 1 RECIST 1.4
NCT00519077 44 2 2013 44 3 RECIST 6.81
Cetuximab
NCT01040832 107 2 2012 53 3 RECIST 1.0 5.7
NCT00671437 42 2 2015 27 1 RECIST 1.0 3.7 ORR is based on CT scans
NCT00661427a 61 2 2012 30 4 RECIST 13.3 Drug dose 500 mg/m2
NCT00661427b 19 2 RECIST 10.5 Drug dose 750 mg/m2
NCT00514943 124 2 2013 62 6 RECIST 1.0 9.7 ORR is based on independentcentral review (ICR)
NCT01602315 27 2 2016 35 2 RECIST 1.1 5.7
NCT00939627 55 2 2014 22 1 RECIST 1.1 4.5
NCT01577173 122 2 2015 62 9 RECIST 1.1 14.5
NCT01696955 79 2 2017 38 3 RECIST 1.0 7.9
Temsirolimus
NCT01172769 [15] 42 2 2012 33 0 RECIST 0
NCT01256385 86 2 2013 40 1 RECIST 1.0 2.5
Sirolimus NCT01195922 [19] 37 1 & 2 2015 16 4 RECIST 1.1 25.0 Neoadjuvant treatment
* Objective response rate (ORR) based on Response Evaluation Criteria in Solid Tumors (RECIST).
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3. Discussion
Traditionally, new anticancer compounds are tested on cancer cell lines cultured on top of plastic
wells, followed by testing using xenograft mouse models prior to clinical trials [1]. However, it is
now clear that this strategy remains unsuccessful given the very low predictive value of the drugs’
efficacy in clinical trials [1]. We, thus, hypothesized that this failure is caused by missing the human
physiologically relevant TME. Thus, we developed the first human-derived TME-mimicking matrix,
“Myogel”, in which 66% of its protein content differs from the mouse tumor–derived Matrigel [2,3].
Thus far, we have demonstrated that a human tumor matrix induces the invasion of carcinoma cells
more than mouse sarcoma–derived matrix “Matrigel” [2–4]. In this study, we compared traditional
2D plastic drug screening method with 2D and 3D Matrigel and Myogel. Combining data from
monotherapy clinical trial results for HNSCC to our in vitro drug testing results, we demonstrated
that Myogel improved the reliability of in vitro drug testing.
In solid tumors, cancer cells are influenced by TME containing hundreds of effectors, such as
stromal and immune cells, their cytokines, growth factors, and structural matrix proteins [2]. Clearly,
all of these factors interfere with the chemosensitivity of cancer against anticancer drugs [20]. Due
to the unknown but presumably very large number of such proteins, it is quite difficult to precisely
analyze the factors interfering in drug screening. Unfortunately, this also applies to our drug testing
using Myogel representing the human TME.
Currently, cancer research is consistently moving towards 3D cell culture models for in vitro
studies [20]. Thus, several matrices have been applied, such as Matrigel, collagen, and chemically
defined synthetic hydrogels [21]. All of these matrices miss a broad spectrum of both human- and/or
tumor-derived structural or signaling molecules. We, thus, hypothesized that a human tumor–derived
matrix would provide a more appropriate TME for the cells and, therefore, a more in vivo–relevant
drug response.
Cell number measurement using imaging technique is not the optimal way to compare cell density
in different matrices due to alternated cell morphology (spheroid in Matrigel and stellate-shaped in
Myogel) and 3D growth (Figures S3 and S4). In this study, we used the CellTiter-Glo luminescent assay
to determine the number of viable cells in culture plates. Even though some Matrigel wells showed
low cell density under microscope, the luminescent assay readouts indicated similar or even larger
number of viable cells compared to 2D and Myogel wells (Figure S4). This was because the cells on
Matrigel are tightly packed together forming spheroid structures. We also did not find correlation
between alternated cell growth in different matrices and the drug response.
The EGFR inhibitors were considered promising anticancer drugs for HNSCC. However, only
modest response rates have been found [22]. Among all EGFR inhibitors, only cetuximab has been
approved by the Food and Drug Administration (FDA) for HNSCC. Unfortunately, its impact has
remained quite limited, and even responsive patients rapidly developed drug resistance [6,22]. Other
EGFR inhibitors, such as gefitinib, have failed in phase III clinical trials despite their promising results
in preclinical in vitro and in vivo animal studies [6,7,9–11]. Interestingly, in our setting, both plastic and
Matrigel yielded higher response rates than the clinical outcomes of the EGFR inhibitors. This might
explain why so many EGFR-targeted drugs successfully passed preclinical testing and subsequently
failed during clinical trials [1]. Yet, EGFR inhibitors tested using Myogel wells exhibited similar
response rates to the 16 monotherapy clinical trial results (with a total of 1258 patients).
In order to understand the mechanism behind the variable cell responses to EGFR and MEK
inhibitors in different culturing conditions, we studied the protein expression of EGFR, ERK1/2, and
pERK1/2 in five cell lines which revealed the most differential EGFR- and MEK-inhibitor effects
between Myogel and the other testing conditions. After repeating the experiments three times, we
could not see any clear difference in the protein levels of EGFR, ERK1/2, and pERK1/2 in these culture
conditions. Therefore, there was no correlation between the protein levels and responses to EGFR and
MEK inhibitors (Figure S5). Our in vitro results are in line with the in vivo results, which showed
that EGFR protein expression and its gene copy number have failed as a predictive biomarker in
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numerous studies [12]. Additionally, previous in vitro study on HNSCC cell lines showed that EGFR
amplification or overexpression was only weakly associated with EGFR inhibitor response [23]. While
many studies report EGFR overexpression in HNSCC, supporting data are inconsistent and limited
due to the large variation in antibodies, the lack of controls, and testing only at the RNA level [24].
One study revealed that EGFR protein overexpression more commonly occurs in established HNSCC
cell lines (n = 14) than in clinical samples (n = 55) [25]. Clinical HNSCC samples (n = 55) did not
overexpress EGFR at the protein level compared to healthy mucosa (n = 46) [25].
Several genomic alterations in HNSCC affect the PI3K/AKT/mTOR pathway activation [26], which
plays an important role in cancer initiation and progression. mTOR inhibitors have shown promising
anti-tumor activity in preclinical studies and early stage clinical trials in HNSCC [27]. Based on two
phase II clinical trials, temsirolimus showed promising tumor shrinkage, but this was associated with
no objective response [15]. Our in vitro results, relying on a DSS value of 5 as the cut-off point, did not
predict patient outcome in clinical trials across all testing conditions. However, the majority of the
tested cell lines yielded a low DSS value, close to the cut-off point of 5, which raises questions about the
reliability of that score as a marker for an objective response. In one study, the authors only highlighted
DSS values of less than 10 as non-responders [28]. If the cut-off point is increased to DSS > 10, the
results more closely mirror patient responses. The selection of the most reliable response cut-off point
is crucial and small changes in it could greatly induce the drug response rates, particularly when the
DSS values are close to the cut-off point. Additionally, here we used only monotherapy clinical trials;
those patients typically resistant to traditional treatment. This renders the comparison to the in vitro
results relatively less than ideal. However, we excluded combination therapy trials, since separating
the drug effect from other treatments (radiation or chemotherapy) would be impossible.
Another mTOR inhibitor, sirolimus, has thus far been studied in only one monotherapy HNSCC
clinical trial among 16 patients. It showed an objective response rate of 25% and one complete patient
response [19]. Although our in vitro study revealed a much higher response rate for sirolimus, further
clinical trials are needed to interpret the in vitro results.
Clearly, those drugs which target receptor activities, such as EGFR, are more greatly affected by
the nature of the extracellular environment than those that target cytosolic enzymes, such as mTOR.
This could explain Myogel’s ability to reveal the real response rate for EGFR antibodies better than for
mTOR inhibitors.
We predicted that a 3D culture would provide more reliable drug testing results than 2D
monolayers. However, in contrast, 2D Myogel- and Matrigel-coated wells yielded rather similar results
to 3D cultures for most of the drugs tested. Thus, our data suggest that a 2D-coated culture is suitable
for drug testing purposes as long as the culture contains critical elements of the human TME.
In conclusion, since the human tumor matrix improved the predictability of the in vitro anticancer
drug testing of HNSCC cell lines, we argue that using it would reduce the number of false-positive
preclinical results, the cost of drug development, and the unnecessary suffering of cancer patients.
4. Materials and Methods
4.1. Cell Lines and Anticancer Compounds
We selected 12 of 45 HNSCC cell lines previously tested against 220 anticancer compounds on
plastic (Table S2) [23]. Each cell line was human papillomavirus (HPV)-negative and had wild-type
KRAS. The cell lines were established at the Department of Otorhinolaryngology—Head and Neck
Surgery, Turku University Hospital (Turku, Finland) [29]. Our selected cells included both primary
and metastatic cell lines from different locations of the head and neck region. Cells were also selected
based on their response to EGFR, MEK, and mTOR/PI3K inhibitors by taking both responsive and
resistant cell lines. Additionally, we selected 19 effective or non-effective anticancer compounds,
targeting the EGFR, PI3K-mTOR, and MAPK signaling pathways based on previous drug testing results
(Table S3) [23]. We cultured the cell lines in Dulbecco’s modified Eagle’s medium (DMEM)/F-12 (Gibco,
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31330-038, Waltham, MA, USA) supplemented with 100-U/mL penicillin, 100-µg/mL streptomycin,
250-ng/mL fungizone, 50-µg/mL ascorbic acid, and 0.4-µg/mL hydrocortisone (all from Sigma Aldrich,
St. Louis, MO, USA), and 10% heat-inactivated fetal bovine serum (FBS) (Gibco, 10270-106). All
cell lines were mycoplasma-free, and tested using the PCR Mycoplasma Test Kit I/C (PromoKine,
Heidelberg, Germany; cat no. PK-CA91-1048). Anticancer compound concentrations were selected
based on a previous half maximal inhibitory concentration (IC50) evaluation [28].
4.2. 3D Matrices and Culturing Conditions
We designed different culturing conditions (cells on plastic, on coated wells, and embedded
in matrix; Figure S3) for each clear-bottom 384-well plate (Corning®#3707, Corning, NY, USA). We
used the commercial mouse Engelbreth-Holm-Swarm (EHS) sarcoma matrix, Matrigel (Corning; cat
no. 354234), and the human leiomyoma matrix “Myogel” (invented by our group) [2,3]. The use
of human leiomyoma tissue was approved by the Ethics Committee of Oulu University Hospital
(statement number 35/2014). All prospective liquid handling was performed using an automated
reagent dispenser (BioTEK, MultiFlo™ FX, Winooski, VT, USA).
Myogel and Matrigel were thawed overnight on ice (4 ◦C). We pre-chilled pipette tips and other
equipment in a freezer (–20 ◦C) and 384-well plates on ice. Matrigel and Myogel were diluted with a
cell culture media to 500 µg/mL. Matrices (5 µL) were added to 384-well plates using an electronic
pipette (VIAFLO II, Integra, Zizers, Switzerland) and the plates were centrifuged for 2 min at 300 rpm
at 4 ◦C. Plates were left overnight in a cell culture incubator. In the control plates, only the cell culture
media was added. On the following day, the cells were counted using the Scepter™ 2.0 Cell Counter
(Merck Millipore, Burlington, MA, USA) and suspended to 500 cells/well. The cell density was selected
based on previous publication and optimized to avoid confluence on the last day of the experiment [23].
To the plastic and Myogel- and Matrigel-coated wells, cells were seeded using an automated reagent
dispenser (BioTEK, MultiFlo™ FX, 20 µL, 25 000 cell/mL, 500 cell/well). Matrices for 3D cell embedding
were diluted to a 500-µg/mL protein concentration. Type I rat collagen (500 µg/mL; Corning®, cat
no. 354236) and 1N sodium hydroxide were mixed with Myogel (500 µg/mL) to ensure complete
gelation. For embedding, cells were first mixed with the matrix (Myogel + Collagen I or Matrigel) and
cell suspension was added to the wells using an electronic pipette (Integra, VIAFLO II; 10 µL, 50 000
cells/mL, 500 cell/well). After a 1-h incubation, a culture medium (10 µL per well) was added on top of
the solidified matrix and the plates were returned to the incubator to sit overnight.
4.3. Drug Sensitivity and Resistance Testing
We performed drug sensitivity and resistance testing (DSRT) on HNSCC cell lines cultured in
different matrices. Each drug was tested over a 10,000-fold concentration range. We normalized the
drug effect against positive (BzCl) and negative dimethyl sulfoxide (DMSO) control wells to calculate
the dose–response curves for each drug in each cell line and matrices separately. To quantitatively
profile alternate drug effects, we calculated the drug-sensitivity score (DSS) designed by the High
Throughput Biomedicine Unit (HTB) at the Institute for Molecular Medicine Finland (FIMM). The DSS
score has been described in several studies [13,23,28], and appears to improve the identification of
drug response vulnerabilities in cell lines and among patients by capturing several parameters in a
single metric. These parameters include IC50, the slope of the concentration curve, and the minimum
and maximum responses [13,28].
Our DSRT protocol was adapted from a platform for leukemia cells used previously [13]. DSRT
custom plates were designed at HTB FIMM in Helsinki, Finland. We used five different 10-fold
concentrations for each anticancer drug in the replicates (Table S2). In total, 100-µM Benzethonium
chloride (BzCl) served as the positive cell-killing control and 0.1% DMSO served as the negative control.
The drug plates, containing all drugs except cetuximab (Erbitux, Merck KGaA, Darmstadt, Germany),
were stored in pressurized inert nitrogen gas–filled storage pods (Roylan Developments Ltd., Surrey,
UK). Cetuximab dilutions were added to the drug plates using a liquid handler (Echo®525 acoustic
Cancers 2020, 12, 92 11 of 15
dispenser, Labcyte, San Jose, CA, USA). We used five 10-fold cetuximab concentrations: 0.005, 0.05, 0.5,
5.0, and 49.5 µg/mL (from 0.03 to 340 nM). These concentrations were selected based on literature and
after optimization at the HTB unit [30–33]. Drugs were diluted with a cell culture media, added by
the MultiFlo™ FX automated reagent dispenser, and placed on a plate shaker for 60 min at 1000 rpm.
Diluted drugs were added onto the cell culture plates (10 µL/well) using a pipetting robot (Biomek FX,
Beckman Coulter, Brea, CA, USA). The final volume of each well was 35 µL.
4.4. Cell Viability Assay
After 3 days, the CellTiter-Glo® (CTG) 2.0 Luminescent Cell Viability Assay (Promega, Madison,
WI, USA) was used to determine the efficacy of the drugs. We first imaged the plates using IncuCyte
Live-Cell Imaging System (Sartorius, Göttingen, Germany) to observe cell density (Figure S4). We then
transferred the plates to room temperature for 15 min and dispensed CTG to the assay plates using
the MultiFlo™ FX automated reagent dispenser (30 µL/well). The plates were shaken for 10 min at
450 rpm and then centrifuged for 5 min at 1000 rpm. Complete lysis of the cells was observed under a
microscope. The CTG signal was detected using the PheraStar plate reader (BMG Labtech, Ortenberg,
Germany).
4.5. Data Analysis
The signal measured in the drug-treated wells was normalized against positive and negative
controls for each condition and the quality of each plate was measured using the Z’ factor (Table S4) [34].
For each condition, dose–response curves were drawn based on a percent inhibition of viability and the
drug concentration (Figure S6 and Table S5). The drug screening data analysis including calculation of
the DSS [13] was performed using a pipeline developed at FIMM. The DSRT pipeline is available at
https://breeze.fimm.fi/. The pipeline and scripts used for the drug sensitivity profiles were developed
using the R programming language (Figures S1, S2, and S6) [35].
We conducted the Friedman test using the SPSS software program (version 25, 2017, IBM
Corporation, Armonk, NY, USA) on each drug comparing the five culturing conditions (control,
Myogel 2D, Myogel 3D, Matrigel 2D, and Matrigel 3D) to detect the differences in drug efficacy.
Pair-wise comparisons were performed (SPSS Statistics, version 25, 2017) applying the Bonferroni
correction for multiple comparisons [14].
4.6. Clinical Trial Data Collection
Clinical trial data for 19 anticancer compounds in HNSCC patients were collected until 17 March
2018, from a website maintained by the National Library of Medicine (https://clinicaltrials.gov) and
PubMed. We included only completed clinical trials for drugs used as monotherapies for which the
results were reported. We collected information on the objective response rates (ORRs, measured
according to the response Evaluation Criteria in Solid Tumors, RECIST), the number of patients who
received the monotherapy, and the number of responding patients in one table.
4.7. Meta-Analysis of Clinical Data
We conducted a meta-analysis in order to graphically present the ORRs for the clinical trials
collected, comparing them to the response rates obtained in this study under the five culturing
conditions. In this analysis, we used RStudio, version 3.6.0. The R packages meta, ggplot2, and ggthemes
were used for more specific analyses and for plotting. The ORRs and the confidence intervals were
calculated using the metaprop function from the meta package, and the figures were obtained using the
ggplot functionalities.
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4.8. Immunoblot Analysis of EGFR, ERK1/2 and pERK1/2 Expressions in Growing Cells on Plastic, Matrigel
and Myogel
To examine protein expression, 7.5 × 105 cells were seeded on 25 cm2 flasks without coating or
coated with 1-mg/ml Myogel and Martigel overnight at +37 ◦C. For the immunoblot analysis, we used
five cell lines (UT-SCC-24A, UT-SCC-24B, UT-SCC-42A, UT-SCC-42B, UT-SCC-81), which revealed
the differential EGFR- and MEK-inhibitor effects between Myogel and the other testing conditions
(Figure S1). The cells were cultured for 48 h in a normal culture medium, after which they were washed
three times with PBS and serum-free Opti-MEM (Gibco) was added. After 24 h, the cells were washed
twice with PBS and lysed with an elution buffer (50 mM Tris HCl, pH 7.5, 10 mM CaCl2, 150 mM NaCl,
0.05% (v/v) Brij 35; Sigma Aldrich) with a complete protease inhibitor cocktail (Roche, Basel, Switzerland)
and PhosSTOPTM phosphatase inhibitors (Roche). After removing the cell debris by centrifugation,
the protein concentrations were measured using a DC Protein assay (Bio-Rad Hercules, CA, USA).
Next, 30 µg of a soluble protein were separated under reducing conditions using a 12% sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to an Immobilon
P membrane (Millipore, Burlington, MA, USA). After blocking with the Odyssey® Blocking Buffer
(LI-COR Biosciences, Lincoln, NE, USA), the membrane was incubated with 1:1000 rabbit anti-EGFR
(D38B1; Cell Signaling Technology, Danvers, MA, USA), 1:1000 rabbit anti-p44/42 MAPK (Erk1/2, 9102;
Cell Signaling Technology), 1:2000 rabbit anti-Phospho-p44/42 MAPK (Erk1/2, Thr202/Tyr204, 9106;
Cell Signaling Technology) or 1:2000 mouse anti-β-Actin (8226; Abcam, Cambridge, UK) antibodies
overnight at +4 ◦C [36]. After washing three times for 5 min each with TBS-Tween®20 (0.05%), 1:10000
IRDye® 680RD Goat anti-Rabbit IgG or IRDye® 800CW Goat anti-Mouse IgG secondary antibody
(Licor Biosciences) was added for 50 min at room temperature and the membrane was washed three
times for 5 min each. The Odyssey scanner (LI-COR Biosciences) was used to image the membrane
and we used the Fiji software [37] for quantification of the protein levels. The results were normalized
to the corresponding β-Actin level (original blots shown in Figure S5).
5. Conclusions
Our findings taken together detected varying drug effects between the human tumor–derived
matrix Myogel compared to current 2D and MSDM methods. We found that Myogel in in vitro drug
screening replicates the best results from clinical trials. We suggest that using the human tumor matrix
in preclinical studies will diminish the number of false-positive preclinical results, reduce the cost of
drug development, and minimize the unnecessary suffering of cancer patients.
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figures, Figure S6: Dose–response curves of the drugs for each conditions, Table S1: Response rates for the drugs
tested on the cell lines under all culturing conditions, Table S2: Clinical and pathological characteristics of the
HNSCC cell lines, Table S3: List of the anticancer compounds screened against the cell lines tested in this study,
Table S4: Z’ factor values for each screen, Table S5: Raw screening data using all viability readouts (DSS, EC50,
MAX, and MIN).
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